The circuitry of the human brain is formed by neuronal networks embedded into astroglial syncytia. The astrocytes perform numerous functions, providing for the overall brain homeostasis, assisting in neurogenesis, determining the micro-architecture of the grey matter, and defending the brain through evolutionary conserved astrogliosis programs.
GLIAL EXPLOSION FORMS THE HUMAN BRAIN
The human brain is the most sophisticated and complex system in the universe, as far as we are aware. Indeed, nature compacted ϳ1.5 trillions of cells connected by hundreds of trillions of contacts within the strictly limited volume of the skull, and orchestrated concerted development of neuronal circuits that produce human intellect, which is unparalleled in its computational and creative power by any other device, be it natural or artificial.
The evolution of the nervous system began with an appearance of multicellular organisms, which required coordination of their remote parts to achieve maximal biological success. At the very core of neural elements lies the excitability and intercellular signaling, both appearing very early in the evolution. The very first and primitive forms of life needed to perceive the environmental changes and preserve their internal homeostasis; this function was achieved by membrane ion channels regulating transmembrane ion movements. These transmembrane ion movements formed the basis for intercellular signaling, epitomized in the Ca 2ϩ signaling system. 1 Transmembrane ion gradients and selectively permeable plasmalemma generated uneven distribution of charges in the very vicinity of the plasmalemma, thus stimulating the appearance of voltage-dependent gating mechanisms that laid the foundations for electrical excitability. The voltage-gated channels exist in virtually all living species, and we can find several types of them in bacteria, with the Ca 2ϩ -and K ϩ -selective channels being the most ancient. [2] [3] [4] [5] [6] [7] The bacteria also evolved the first precursor of the Na ϩ channel, the NaChBac expressed, for example, in Bacillus halodurans. 8 In the eukaryotes, the excitable molecules developed further; in single-cell organisms, the waves of plasmalemmal excitation began to generate through the spreading opening/closures of voltagegated channels. 9 In parallel eukaryotic organisms acquired intracellular organelles, intracellular channels dwelling in the endomembranes, and exocytotic machinery formed the basis for chemical intercellular transmission.
The perception of environmental chemical signals is in all likelihood inseparable from life existence, and the proto-cells certainly needed to detect the most basic chemical clues indicating changes in the immediate neighbourhood. We do not know what the very first chemical receptor was originally, yet we do know that bacteria have chemosensitivity and chemotaxis. Even more important, bacteria have developed the sensitivity to biologically produced chemicals, which are accumulating in the cytosol of the living cells and are released when damaged. This sensitivity is strictly survivalism, which allowed the cells to detect the danger signal produced by their dying relatives; yet this formed the basis for future neurotransmission. The first intercellular signaling molecules were ATP and glutamate, which are highly concentrated in the cytosol of living cells. 13 Therefore, the very first multicellular organisms were in possession of several signaling systems associated with plasmalemmal channels, plasmalemmal receptors, and exocytotic machinery. The multicellularity brought with it another signaling mechanism made by transcellular channels (generally known as gap junctions), which established the direct communication route in cellular syncytia. The development of the multicellular species induced specialization of cellular layers and appearance of tissues; the surface layer developed into epithelial cells. The epithelial cells were endowed with ion channels; many of these cells possessed exocytotic vesicles; these epithelial cells were connected by gap junctions, and, most importantly, these cells were in direct contact with the environment. Therefore, it is not surprising that the epithelial cells became the ancestors of the nervous system.
The very first neural elements were diffusely scattered throughout the outer surface of the body of Cnidaria (i.e, jelly fishes, box gellies, sea anemones, and Hydrozoa). These nervous elements are primarily sensory and they are already attaining a degree of specialization. For example, in Hydra the nervous elements are represented by touch-sensitive and photosensitive cells, and they are connected in a simple nervous net through neuritis interwoven in between the epithelial cells.
14 With an increased complexity of organisms the first neuronal conglomerates represented by sensory organs and primordial nerve ganglia have evolved, and this increase in complexity and neuronal specialization coincided with the appearance of neuroglia, which already at this early stage controlled development and functional activity of the neuronal networks. 15, 16 The appearance of the CNS, with its clearly distinct central and peripheral parts was associated with further specialization of neurons and evolutionary progression of neuroglia. The latter became more complex, evolving into several functionally idiosyncratic cellular populations, represented by astroglia, NG-2 glia, and myelinating cells, represented by oligodendrocytes and Schwann cells. The astrocytes and NG-2 cells populate the grey matter, whereas oligodendrocytes and Schwann cells cover and myelinate the axons providing the latter with insulation that greatly increased action potential conduction velocity. The microglial cells are migrants, the cells of myeloid origin that invade the brain in the early postnatal period and form the neural immune/defence system. Therefore, the neuroglia assumes full responsibility for the nervous system homeostasis and defense.
The evolution of the primate brain and the emergence of intellect coincided with dramatic changes in neuroglia. First, the numbers exploded, and the neuroglia became the most numerous cell type in the human brain, outnumbering neurons by several times. 17 Second, the morphology had also changed; the human protoplasmic and fibrous astrocytes are 2 to 3 times larger as compared to rodents. 18, 19 Even more importantly, the human astrocytes are immensely more complex 18 ; each human astrocytes has ϳ10 times more primary processes than the rodent one; the arborization is also infinitely more complex and human protoplasmic astrocyte covers and integrates ϳ2 million synapses, whereas rodent astrocytes cover ϳ20,000 to 120,000 synaptic contacts. In addition, several primate specific astrocytes (e.g. interlaminar and polarized astrocytes) are involved in interlayer integration in the cortex. 18, 19 
FUNCTIONS OF ASTROGLIA

Structural function
All neural elements develop from the neuroepithelial cells that at the very beginning of the embryogenesis gave birth to radial glia, which served as both the source of neural precursors and the scaffold that allowed neural cells to reach their final destination in the grey matter. The astrocytes, being direct descendants of the radial glia, shape the grey matter through the process of tiling. 20 -22 Every protoplasmic astrocyte occupies it own territory, where its processes cover neuronal membranes and synaptic contacts. The astrocytes also send processes to the neighboring blood vessels, and in this way they form a neurovascular unit.
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Metabolic support
The neurovascular unit provides for a metabolic connection between blood vessels and parenchyma of the brain. First, astrocytes integrate the neuronal activity with the local blood flow being responsible for the functional hyperaemia, which is manifested by a rapid vasodilatation after a local increase in neuronal firing. The increased synaptic transmission induces astroglial Ca 2ϩ signaling that travel to the perivascular processes of astroglial cells and triggers release of vasoactive substances from the endfeet. 23 
Brain homeostasis
The brain function is impossible without tight control over the extracellular environment, which includes regulation of extracellular concentrations of ions, metabolites, and neuroactive molecules. Extracellular ion homeostasis is particularly important for K ϩ ions, because the latter are accumulated in quantities during neuronal activity, due to repetitive opening of neuronal K ϩ channels with subsequent K ϩ efflux. Increase in extracellular K ϩ concentration in turn depolarizes neuronal membranes, thus altering their excitability. In physiological conditions, extracellular K ϩ can rise from ϳ5 mM to 10 to 12 mM during periods of robust neuronal activity; in pathology, K ϩ can rise much higher, attaining levels of up to 50 mM. 29 Extracellular K ϩ homeostasis is mainly carried out by astrocytes through local K ϩ uptake (via inward rectifier K ϩ channels) and spatial K ϩ buffering. 29 ] o . This K ϩ uptake and spatial buffering is coupled with astroglial water transport. Increases in synaptic activity are associated with local decreases in extracellular volume, which is regulated by water transport across astroglial membranes and water redistribution through the glial syncytium. Astroglial water transport is functionally linked to activation of water channels aquaporins that are concentrated in perisynaptic processes and in the astroglial endfeet structures. 31 Astroglial cells are central elements of homeostasis of neurotransmitters in the brain. They are particularly important for homeostasis and turnover of the main excitatory neurotransmitter glutamate being the main sink of glutamate in the brain; from the bulk of glutamate released during synaptic transmission, approximately 20% is accumulated into neurons, whereas the remaining 80% is taken up by perisynaptic astrocytes. 32, 33 Removal of extracellular glutamate from the extracellular space is vitally important for preventing its excitotoxicity. Astroglial glutamate transport is the function of specific glutamate transporters excitatory amino-acid transporter 1 and excitatory amino-acid transporter 2, which are expressed exclusively in astrocytes. 34 Glutamate transport is driven by transmembrane gradient for Na ϩ translocation of every glutamate molecule, which is accompanied by an influx of 3 Na ϩ ions and 1 H ϩ ion, coupled with the efflux of 1 K ϩ ion, making this transport electrogenic. 35 Activation of glutamate transporters is associated with substantial Na ϩ fluxes and increase in [Na ϩ ] i , 36 which serves as a signal for a glucose-lactate shuttle described in the previous section. The excess of intracellular Na ϩ is removed by sodium-calcium exchanger, which is conveniently co-localized with glutamate transporters in perisynaptic processes; increased [Na ϩ ] i turns the exchanger into the reverse mode, thus rapidly reducing cytosolic Na ϩ loads.
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The glutamate accumulated by astrocytes is critically important for the overall glutamate turnover in the brain. Glutamate after entering astrocytes is converted into glutamine by the glutamine synthetase. 39 The nontoxic glutamine is then transported back to the presynaptic terminal through the extracellular space; in the neuronal cytoplasm glutamine is converted back into glutamate, which is accumulated by synaptic vesicles, thus accomplishing the glutamate-glutamine shuttle.
Signaling in neuronal-glial circuits 1) Glial cells express neurotransmitter receptors.
Glial expression of neurotransmitter receptors was discovered in 1984 when glutamate and GABA-induced electrical responses were recorded from cultured astrocytes and oligodendrocytes. 40 -42 Subsequent in vitro experiments have demonstrated that glial cells express the very same diverse variety of neurotransmitter receptors and ion channels as do neurons, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] thus raising the question of the role for neuroglia in information processing in the brain. Further experiments have found that the expression pattern of neurotransmitter receptors in situ is very much restricted by the immediate neurotransmitter environment; as a consequence glial cells are properly endowed to sense the neurotransmitters released in their territorial domains. 56 -59 The expression of neurotransmitter receptors in astrocytes from different brain regions is extremely heterogeneous; although most of astroglial cells express receptors to purines and to glutamate. 33,60 -62 Importantly, astrocytes and oligodendrocytes possess a special type of NMDA glutamate receptors, which, in contrast to neurons, are devoid of Mg 2ϩ block [63] [64] [65] and therefore can be activated at characteristically negative glial resting potentials (approximately ϳ80 to -90 mV).
2) The tripartite synapse. The synapses in the CNS are formed by three elements: by the pre-and postsynaptic neuronal compartments and by the astroglial perisynaptic processes. This structure is generally known as a tripartite synapse. 66, 67 The neurotransmitters released in the course of synaptic transmission from the neuronal terminal are stimulating the astroglial receptors of both ionotropic and metabotropic varieties, 33, 62 thus providing the information input to neuroglial circuitry.
3) Signaling in astroglial syncytia. In contrast to neuronal networks, which are constructed from physically separated neuronal cells, astrocytes are integrated into physically continuous structures known as astroglial syncytia. This integration is achieved through the gap junctions expressed in the peripheral portions of astroglial processes. The gap junctions are formed by intercellular channels, the connexons. 68 The latter create relatively big pores, which span through the plasmalemma of adjacent cells. The connexon pore is permeable to molecules with molecular weight ϳ1 KD and it is instrumental for long-range glial signaling. Astroglial syncytia are anatomically localized and segregated; for example, in somatosensory cortex these syncytia are confined to individual barrels and do not have inter-barrel connectivity. 69, 70 The intercellular communication route provides the substrate for astroglial long-range signaling. Indeed, the glial cells are electrically nonexcitable and are unable to generate propagating action potential. Nonetheless, astrocytes are using the intracellular organelle, the endoplasmic reticulum (ER) to generate intra-and intercellular signals. The ER has many functions, which include protein synthesis and post-translational protein modification, as well as intracellular transport of various molecules. In addition, the ER acts as a universal dynamic intracellular Ca 2ϩ store, [71] [72] [73] [74] [75] The ER membrane contains Ca 2ϩ pumps (the sarco[endo]plasmic reticulum ATP-ases (or SERCAs) that transport Ca 2ϩ into the ER lumen. 80 The intra-ER Ca 2ϩ concentration is very high (range, 0.5 to 1 mM), 81, 82 which creates a steep concentration gradient aimed at the cytosol. Importantly, the lumen of the ER is internally continuous and Ca 2ϩ can rapidly equilibrate within the organelle through unopposed diffusion. 83 [93] [94] [95] [96] These propagating glial Ca 2ϩ waves are the most thoroughly investigated mechanism of long-range glial signaling; nonetheless, many other molecules (e.g., metabolic substrates, ATP, or other second messengers) can also participate in signaling within astroglial circuits.
4) The gliotransmission. Excitation of astroglial cells and astroglial Ca 2ϩ waves trigger the release of gliotransmitters. These gliotransmitters include glutamate, ATP, D-serine, GABA, taurine, and mediate glialneuronal and glial-glial signaling. [97] [98] [99] [100] [101] [102] [103] The leading mechanism for gliotransmitters release is exocytotic, [104] [105] [106] although diffusion though large-pore plasmalemmal channels can also be involved.
107-110
5) Glia and information processing in the brain.
The ability of neuroglia to detect neurotransmitters, to produce active responses after stimulation of various receptors to generate propagating signals and to release gliotransmitters, naturally questioned their role in the information processing in the brain. We already know that astrocytes may actively modulate transmission in neuronal networks and affect synaptic plasticity 111 ; we may also assume that astroglial circuits can, together with neurons, participate in cognition, learning, and memory. However, this remains an assumption, and more experimental data are required to understand the role of glial cells in higher brain functions.
NEUROLOGICAL DISORDERS AS GLIOPATHOLOGY: THE ROLE OF ASTROGLIA
Diseases of the nervous system remain the most difficult to handle and to cure; the therapeutic advances in neurology are at best modest when compared to other branches of medicine. The reason is simple; it is the singular complexity of the human brain and its connections, both morphological and functional.
For a long time the neurocentric view dominated the neuropathological theories, although the pathological potential of glia was already acknowledged by prominent neuropathologists of the 19th century, such as Alzheimer, 112 Frommann, 113 and Nissl. 114 Nonetheless, it is now clear that it is neuroglia, which determines the progression and outcome of most, if not all, neurological diseases. 115, 116 Indeed, the brain homeostasis is managed solely by the neuroglia, and the failure of neuroglia to maintain this homeostasis is fatal for the nervous tissue. This is particularly manifest in the ischemic insult in which performance of astroglia very much determines the development of the ischemic core and its relations with penumbra. 117 In addition, the astroglia possess a specific defensive mechanism, (i.e., the astrogliosis that is activated in response to brain insults). 118, 119 The astrogliosis is fundamental for limiting the areas of damage (by scar formation through anisomorphic astrogliosis) and for the post-insult remodeling and recovery of neural function (by isomorphic astrogliosis).
Astroglia is involved in pathogenesis of many chronic neurological disorders. 67, 120 For example, astrocytes undergo remodeling in the epileptic brain, which includes both morphological and functional changes. 121, 122 Astrocytes are also important for pathogenesis of various psychiatric disorders. The astrocytes may play an important role in schizophrenia, because failures in astroglia-dependent glutamate homeostasis can result in neurotransmission disbalance.
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ASTROCYTES IN NEURODEGENERATIVE DISEASES
The neurodegenerative disorders are arguably the most fearsome human diseases because they destroy our intellect and reduce human beings to the animal state. The neurodegenerative diseases are also uniquely the property of mankind, because as a rule they do not occur in animals, making one wonder whether they may represent a price for the exclusive power of our brain. The neurodegenerative processes start with disruptions in the connectivity within the brain circuitry, 124 -127 which affect cognitive functions and underlie the early stages of the disease. Further pathological development of the neurodegenerative process results in neural cell death and general atrophy of the brain, manifested by the disappearance of higher brain functions.
The pathological potential of astroglia in neurodegeneration began to be explored only very recently, as for a long time neurodegenerative diseases were associated primarily with neuronal death. Nonetheless, it is quite obvious now that the astroglia is invariably affected at the early stages of neurodegenerative process, and this determines to a large extent the progression and severity of the disease. Several recent investigations discovered astroglial atrophy, which appears at the very early stages of different neurodegenerative diseases. Conceptually atrophic changes in astrocytes may lie at the very core of initial disruption of neural circuitry, as reduced astroglial support affects maintenance and performance of synapses. Several articles, published in this special issue discuss the role of neuroglia in various neurodegenerative processes in detail; here we shall briefly overview evidence for astroglial atrophic changes in the most frequent forms of neurodegenerative diseases.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) described by Charcot 128 and Charcot and Joffroy 129 is manifested by the degeneration of motor neurons from the cortex, the brain stem, and the spinal cord. The causes and aetiology of ALS remain generally unknown, although approximately 20% of cases are associated with dominant mutations in the gene coding for Cu-Zn superoxide dismutase (SOD1). 130 Neuroglial reactions play an important role in ALS pathology. Prominent astroglial degeneration and atrophy was found in the h(uman)SOD1 G93A transgenic mouse; this astrodegeneration preceded both neuronal death and the appearance of clinical symptoms. 120, 131 Incidentally, the ALS astrocytes (expressing hSOD1) were specifically sensitive to glutamate, and contrary to healthy astrocytes they displayed glutamate excitotoxicity. 120, 131 Even more importantly, selective silencing of the SOD1 mutant gene in astrocytes significantly slowed the progression of ALS in transgenic mice. 132 Late stages of ALS are characterized by significant astrogliosis and astroglial proliferation.
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Parkinson's disease
The symptoms of Parkinson's disease (akinesia, rigidity, tremor at rest, and postural abnormalities 135 ) develop because of specific degeneration and demise of dopaminergic neurons in substantia nigra. The role of astrocytes in the pathogenesis of the Parkinson's disease has not been characterized; although astrogliosis was detected at the late stages of the disease. 136, 137 At the same time substantia nigra, in which Parkinson's disease pathology primarily develops, has a low density of astrocytes compared to other brain regions and early astroglial atrophy may have a pathological significance; astrodegeneration can result in diminished support of domapinergic neurons associated with an increase of their vulnerability. However, this hypothesis has to be experimentally tested.
Non-AD dementia
Profound changes in astrocytes are observed in many types of non-AD dementia-related neurodegeneration. For example, the early stages of frontotemporal dementia are characterized by significant astroglial degeneration and apoptotic death of astrocytes. 138 Importantly, the depth of glial atrophy correlated with the severity of dementia. However, other studies found prominent astrogliosis in postmortem tissues form patients with frontotemporal dementia. 139 Similarly, prominent astrogliosis leads to the development of thalamic dementia, in which neuronal loss is secondary to pathological remodeling of astroglia. 140 Both astrogliosis and astroglial atrophy were observed in immunodeficiency virus-1 (HIV-1) associated dementia, in which astrogliosis in the initial phase is followed by significant astro-cytic death; the loss of astrocytes correlates with the severity of cognitive impairments. 141, 142 Astrocytes can also be a target for tau pathololgy, and specific expression of tau protein in astroglial cells can trigger agedependent neurodegeneration. 143, 144 Impairment of astroglia is also involved in pathogenesis of Wernicke encephalopathy, which is associated with a very substantial reduction in expression of astroglial glutamate transporters; this results in compromised clearance of glutamate with subsequent neuronal death through excitotoxicity.
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Astroglia in Alzheimer's disease
The pathological modification of astrocytes in the demented brains were initially observed by Alois Alzheimer, 112 who had found glial cells abundantly populating neuritic plaques. The reactive astrogliosis has been subsequently confirmed to be an archetypical morphological feature of plaque-infested Alzheimer's disease (AD) brains at the late stages of the disease (FIG. 1) ; this astrogliosis was observed in both human tissues and in the brains isolated from AD animal models.
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Morphology and numbers
Knowledge about the role of neuroglia in the progression of AD remains fragmentary, at best. Generalized astrogliosis, manifested by cellular hypertrophy and by an increase in expression of GFAP and astroglial S100B protein, was routinely observed in postmortem tissues from AD patients. 148, [151] [152] [153] [154] [155] [156] More detailed analysis of astrogliosis in the brains obtained from old patients (with and without confirmed AD) have demonstrated a correlation between the degree of astrogliosis and cognitive decline; however, the same analysis failed to reveal a direct correlation between astrogliotic changes and senile plaques. 157 The morphological data showed reactive astrocytes associated with some, but not with all A␤ plaques; astrogliotic fields were also found in areas without A␤ depositions in both AD and non-AD brains. 157 Moreover, there is no significant difference in GFAP expression in demented versus nondemented brains. 158 The A␤-independent astrogliosis may accompany normal brain aging, although the age-dependent changes of astroglia are in urgent need of proper investigation. The data describing astroglia in aged brains are scarce and controversial. For example, in rat retinal preparations, aging was associated with a decrease in the total number of astrocytes and with an increase in the proportion of cells with gliotic morphology. 159, 160 Conversely, a rather significant (by one third) increase in the number of astrocytes was observed in hippocampus of female B57 mice 161 ; similar age-dependent increase in astrocytes quantity was found in the CA1 hippocampal area and in the frontal cortex of male Sprague-Dawley rats; this was accompanied with hypertrophic remodeling that was more prominent in the cortex. 162 An increase (by ϳ20%) in the number of astrocytes was detected in parietal cortex and the dentate gyrus of old Wistar rats. 163, 164 No change in the number of astroglial profiles was found in the primary visual cortex of old rhesus monkeys 165 ; similarly, the quantity of astrocytes in the human neocortex did not change with age. 166 Significant increase in GFAP expression and astroglial hypertrophy was detected in the white matter of the brains of senescent monkeys, hinting for specific age-dependent alterations in axonal connectivity in the CNS. 167 Overall, not much in known regarding astroglia in the aged human brain; the generally accepted notion of an increased astrogliosis and increased astroglial numbers in the senescent brain 168 has to be corroborated by further meticulous morphological analysis.
Astrogliosis and astroglial degeneration in AD
Reactive astrogliosis in AD can be initiated by several factors, which include signaling from damaged neurons/ neuroglia, as well as extracellular deposition of the ␤-amyloid peptide (A␤); the latter was shown to trigger astrogliosis in vitro. 169 ] i oscillations, which somewhat contribute to astroglial neurotoxicity. 170, 171 The abnormal, spontaneous Ca 2ϩ oscillations and Ca 2ϩ waves were also observed in vivo in astrocytes associated with neuritic plaques. 172 Furthermore, astrocytes in A␤ overexpressing transgenic mice demonstrated increased coupling in neocortical regions and had elevated expression of AMPA/kainate glutamate receptors and glutamate transporters. 173 In contrast, A␤ was reported to decrease expression and capacity of glutamate-aspartate transporter and glutamate transporter-1 mediated glutamate uptake in cultured astrocytes. 174 The activated astrocytes are intimately involved in the neuro-inflammatory component of the AD through the release of cytokines, proinflammatory factors, and nitric oxide/reactive oxygen species neurotoxicity. 124 At the early stages of the AD pathology in the tripletransgenic mice (3xTg-AD), harboring the mutant genes for amyloid precursor protein (APP Swe ), presenilin 1PS1 M146V , and tau P301L 175 ), the reduction in the morphological presence of astrocytes, indicative of astroglial degeneration/atrophy, was discovered. 149, 150 In these experiments, the GFAP-positive astrocytes were morphologically analyzed in hippocampi of the 3xTg-AD mice of different ages (range, 3 to 18 months). It must be noted that GFAP labeling differs profoundly between brain regions; in hippocampus ϳ80% of astrocytes are GFAPpositive. 176 There were no significant age-dependent changes in the density of astrocytes in both control and AD brains. Already from 6 months of age, the astrocytes in CA1 and dentate gyrus of 3xTg-AD animals showed atrophic signs (i.e., decrease in the volume of GFAPstaining, decreased size of somatas, and decrease in number of processes (FIGS. 1 and 2). These changes became fully significant at older ages (range, 9 to 18 months). 149, 150 Importantly, the appearance of senile plaques, which in the 3xTg-AD model occurs at 12 months of age in the CA1 region and at 18 months of age in the dentate gyrus, triggered morphological astrogliosis, but only in astrocytes directly associated with A␤ deposits; the astroglial cells distant to plaques remained atrophic. 149, 150 Interestingly, that astroglial atrophy (manifested by decreased complexity of processes) was observed in postmortem analysis of the neocortex of demented patients.
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Astroglia and ␤-amyloid
The role of astroglia in A␤ processing and metabolism represents another controversial matter. The reactive astrocytes in AD were suggested to participate in the clearance and degradation of ␤-amyloid (for review see References 178 -180 ). Indeed, activated astrocytes located in the close vicinity to A␤ plaques formed in the brains of transgenic APP mice were found to express neprilysin, the amyloid-degrading enzyme. 181 Accumulation of A␤ was observed in astrocytes from entorhinal cortex of AD patients, 147 although it was rarely found in astrocytes from 3xTG-AD mice. 149, 150 Functional experiments also demonstrated the ability of astrocytes to phagocyte and degrade ␤-amyloid deposits in an in vitro system. 182 However, these experiments also demonstrated ␤-amyloid sequestration can be done only by astrocytes isolated from healthy brains; the astroglial cells obtained from APP transgenic mice were ineffective. 182 At the same time, the AD conditions may affect astroglia, turning them into A␤ producers. Production of A␤ requires the endoprotease known as ␤-site APP-cleaving enzyme 1 ([BACE 1] also referred to as ␤-secretase). In the healthy brain expression of BACE 1 seems to be exclusively confined to neurons. In conditions of ADlike pathology or even under chronic stress, astrocytes start to express BACE 1, thus acquiring A␤Ϫproducing ability. 178 Astroglial BACE 1 was detected in activated astrocytes surrounding A␤ plaques in several transgenic AD mice models, such as Tg2576 183 and double mutated K670N-M671L APP. 184, 185 Various brain insults that triggered astrogliosis (e.g., immunolesion of cholinergic septohippocampal afferents or occlusion of middle cerebral artery) also triggered astrocytic expression of BACE 1. 178 Similarly, increased APP production was detected in the rat model of chronic neocortical astrogliosis, induced by grafting foetal cortical tissue in the midbrain of neonatal animals; chronically activated astrocytes were immunostained for APP as well as for another AD-related marker apolipoprotein E.
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The neurovascular unit in AD: role for astrocytes Vascular impairments represent an important factor in the pathology of AD. Numerous imaging studies of humans have found that significant reduction in blood flow in the brains of patients with AD and AD-like status indicated the role for vascular defects at the early stages of the disease (see References [187] [188] [189] for comprehensive review). Morphological analysis also found pronounced vascular pathology in AD brains. 190 The elementary component of brain microcirculation is represented by a neurovascular unit, in which astrocytes integrate neurons, brain endothelium, pericytes, and vascular smooth muscle cells into a functionally independent entity. 23, 188, 189 In this structure, astrocytes assume the role of coordinating elements that establish the link between neuronal activity and local blood flow through several signaling cascades controlling vasoconstriction and vasodilatation. 23, 24, 26 Furthermore, astroglial endfeet, which plaster brain capillaries, regulate formation of tight junctions (i.e., controlling the bloodbrain barrier) and have a central role in the transport of water and electrolytes, as well as in the utilization of glucose and providing neurons with energy substrates. 28, 31, 189, 191 In AD, the neurovascular unit is specifically targeted because A␤ plaques often encompass brain capillaries (FIG. 1) , thus affecting microcirculation and vascular A␤ clearance. 187 At the same time, the primary vascular pathology induces overproduction of A␤ through yet poorly characterized mechanisms. 188 Control of local cerebral circulation and functional hyperemia accomplished by astrocytes is of fundamental importance for functional activity of neural networks. Pathological remodeling of the neurovascular unit that occurs in AD is likely to be associated with specific damage to astroglia, which may occur at the early stages of the disease and contribute to cognitive abnormalities. Presently, the mechanisms of AD-specific astroglia damage remain unknown, although atrophy of astrocytes may be also linked to neurovascular unit dysfunction.
Metabolic remodeling of astroglia in AD
Metabolic stress represents one of the early symptoms of AD-like pathology. Numerous functional imaging studies demonstrated significant and progressive decrease in glucose use from the very early stages of AD in humans. 192 The A␤ remodels astroglial metabolic phenotype in vitro by affecting glucose metabolism and increasing reactive oxygen species production in cultured astrocytes. The data on actual mechanisms of A␤-dependent changes in glucose metabolic pathways are controversial. Several groups have found that A␤ decreased the astroglial use of glucose. [193] [194] [195] In contrast, treatment with A␤ significantly increased glucose use in cultured astroglial cells by enhancing the activity of all major glucose metabolism pathways and glycogenesis. 196 Furthermore, co-culturing neurons with astrocytes pre-treated with A␤ significantly decreased neuronal survival as compared with co-culturing with naive astrocytes. 196 Analysis of the activity of metabolic enzymes similarly yielded controversial results: both decrease 197, 198 and increase 195, 199 in the activity of enzymes associated with glucose metabolism have been reported in AD brain preparations. These discrepancies may reflect opposite cell-specific changes in glucose metabolism developing at different stages of AD.
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Astrodegeneration and failed synaptic connectivity: astroglia drive early cognitive decline in AD?
Cognitive deficits are the first signs of AD, which occur well before the development of disease-specific histopathology manifested by the appearance of senile plaques and neurofibrillary tangles. 200, 201 This observation indicates disruptions in neural connectivity. These disruptions occur at the early stages of the disease and are responsible for the decline of the brain function. Numerous studies have demonstrated that synaptic weakness and synaptic loss are the earliest morphological correlates of the AD. 127, 200 Moreover, clinical studies confirmed a strong correlation between the degree of dementia and the extent of synaptic loss. [202] [203] [204] In contrast, there is a rather poor correlation between the level of A␤ load and tangles expression and cognitive function.
Mechanisms of early synaptic failure in dementia and AD are obscure. Of course, synaptic loss may reflect neurodegenerative process solely associated with mal-function of neurons; yet the central role of astrocytes in brain homeostasis may justify alternative, astrocentric hypothesis (FIG. 3) . Indeed, astrocytes are fundamentally important for synaptogenesis and synaptic maintenance. Astroglial transporters control the composition of the extra-synaptic environment and prevent local toxicity of glutamate or local depolarizations by excessive accumulation of K ϩ ions. The glutamate-glutamine shuttle, expressed in astroglia, sustains neuronal glutamate levels, thus maintaining glutamatergic transmission. Finally, astrocytes provide local metabolic support, which, assuming excessive energy demands of synaptic compartment, 205, 206 is critically important for neurotransmission. Therefore, we may suggest that atrophy of astroglia, which occurs at the early stages of AD and is likely to accompany early stages of other neurodegenerative diseases, determines synaptic malfunction, synaptic loss, and cognitive deficits.
FIG. 3.
Astroglial hypothesis of Alzheimer's disease (AD). The initial impairments of brain connectivity and synaptic transmission observed in AD (and possibly in other neurodegenerative diseases) can result from generalized atrophy of astrocytes. Atrophy of astroglia may cause reduced synaptic coverage, affect homeostasis of ions and neurotransmitters, alter neurovascular unit performance, and reduce metabolic support to neurons. These factors can contribute to synaptic malfunction and synaptic loss, thus causing early cognitive deficits. At the later stages of AD, appearance of senile plaques presents a strong pro-gliotic signal, which triggers activation of both astrocytes and microglia. Reactive astrocytes further reduce synaptic support and may exacerbate microglial activation. Reactive glia release inflammatory and neurotoxic factors, which induce neuronal death and brain atrophy, thus causing severe dementia. (Drawings of astrocytes were kindly provided by Prof. M. Nedergaard.)
Therapeutic implications
At present, there is no cure for AD or other neurodegenerative diseases; existing therapy is purely symptomatic. Numerous attempts to target ␤-amyloid depositions, although successful in reducing A␤ load, did not improve either cognitive status or disease progression. 207 Can the discovery of pathological relevance of astroglia lead to a cell-specific therapy/prevention of AD? Several strategies can be suggested.
First, the astroglia-specific molecules can be specifically targeted. The obvious candidate is GFAP, which is increased in reactive astrocytes. Reduction of GFAP expression affects synaptic plasticity, 208, 209 whereas increase in GFAP expression induces various forms of encephalopathy and alters synaptic activity. 168 Conceptually, levels of GFAP expression can be affected by steroid hormones 168 and even by caloric restriction. 210 However, this strategy can be effective at the later stages of the AD characterized by prominent astrogliosis. Second, molecules can be designed to affect astrocytespecific homeostatic cascades (e.g., astroglial glutamate uptake). The neuroprotective drug Riluzole, 211 which inhibits neuronal glutamate release was also reported to enhance astroglial glutamate uptake. 212 Incidentally, the beta-lactam antibiotics, (e.g., represented by penicillin and ceftriaxone) increase astroglial expression of glutamate transporter-1 through gene activation. 213 Both compounds are considered potential drugs for the treatment of motor neuron diseases associated with glutamate excitotoxicity, resulting from astroglial deficiency. 214 Similar strategies may be adapted to the treatment of AD by reducing excitotoxic neuronal death and improving synaptic function.
However, the most promising strategy seems to be aimed at long-term modulation of astroglial function by promoting endogenous cell proliferation and differentiation. As astrocytes have some stem cell properties and can (at least in principle) re-enter the cell cycle, manipulation with these abilities can develop the true cellspecific therapy, which can be used for arresting AD progression at the very early stages.
CONCLUSIONS
Astrocytes are the central element of brain homeostatic system, which through their multiple functions provide for maintenance and defence of neural networks. Astroglial cells are specifically involved in various neurological diseases, determining their pathogenesis and outcome. Astrocytes are involved in all types of neurodegenerative processes, and display prominent remodelling in the AD; early dystrophic changes in astroglia can represent an important step in initiation and progression of Alzheimer's disease. Targeting of astroglia may provide a new principle for treatment of AD at the early stages of the disease.
